ENTITY
Wuxi Biologics

Wuxi Biologics (2269 HK)

707
Analysis
Health Care • China
Wuxi Biologics is a global Contract Research, Development, and Manufacturing Organization (CRDMO) offering end-to-end solutions for biologics discovery, development, and manufacturing, including complex modalities like monoclonal antibodies and antibody-drug conjugates. The company provides comprehensive services from concept to commercialization, including vaccine CRDMO services. It was founded in 2010 and is headquartered in Wuxi, China.
more
bullish•Quantitative Analysis
•29 May 2026 10:49

Hong Kong Buybacks Weekly (May 29th): Tencent, AIA, Xiaomi, Wuxi Biologics

We analyzed the Hong Kong buyback data in the past week and highlight the top 3 companies that repurchased the most shares were Tencent (700 HK),...

Logo
131 Views
Share
•15 Jan 2019 06:58

2018 HK-Connect SouthBound In a Nutshell

Since autumn of 2014, the HK-Shanghai Connect, and later the HK-Shenzhen Connect mechanisms have provided means for mainland investors to buy Hong...

Logo
874 Views
Share
•30 Nov 2018 05:53

G20 Game of Roulette:  Where Will Trump-Xi Ball Land? + 2018 Holiday Season Conviction Shorts

From conversations with investors, we believe that the market strongly expects a “positive” outcome whereby the US agrees to freeze the trade...

Logo
626 Views
Share
•26 Jun 2018 15:55

Trade Risks Start to Impact, as China Biotech Ambitions Grow…

Cyclical indicators are softening this month - new orders index for the Philly Fed fell nearly 23 points while Japan’s PMI new export orders...

Logo
311 Views
Share
bearish•Everest Medicines
•05 May 2026 07:14

Hang Seng Biotech Index Rebalance Preview: One Set of Changes in June

InSilico Medicine Cayman could replace Everest Medicines in the index in June. Estimated one-way turnover at the rebalance is 2.2% resulting in a...

Logo
300 Views
Share
x